Schizophrenia: General Findings and Current Status by Srivastava, Amresh
Western University
Scholarship@Western
Psychiatry Presentations Psychiatry Department
2-2007
Schizophrenia: General Findings and Current
Status
Amresh Srivastava
University of Western Ontario, amresh.srivastava@sjhc.london.on.ca
Follow this and additional works at: https://ir.lib.uwo.ca/psychiatrypres
Part of the Psychiatry and Psychology Commons
Citation of this paper:
Srivastava, Amresh, "Schizophrenia: General Findings and Current Status" (2007). Psychiatry Presentations. 22.
https://ir.lib.uwo.ca/psychiatrypres/22
Schizophrenia : General 
Findings and Current status
Amresh Shrivastava
Mumbai
Genetic Risk Of Schizophrenia
General population 1%
Second degree Relative 2.5%
Parents 3.8%
Sibling 8.7%
Child, 1 parent 12%
Child, 2 parents 30-40%
Twin Monozygotic 40-50%
Risk factors for schizophrenia
Genetics
Pre-or-perinatal events
Factors during childhood 
and adolescence
Psychological and 
electrophysiological 
characteristics of schizophrenia
Cognitive dysfunction
Neurophysiologic 
dysfunction
Schizophrenia1%
Schizophrenia-related
Personality Disorders5%
Brain Structure and 
Function in schizophrenia
Brain Structure
Brain Function
Theories of schizophrenia
Dopamine
Neuronal System
Neurodevelopmental factors
Limbic structures
Postmortem studies in 
schizophrenia
Established by systematic reviews:
Enlargement of lateral and third ventricles          
(+ 25%-40%)
Smaller brain volume (-3%)
Smaller Grey matter volume (-6%)
Relatively smaller medial temporal lobe volume 
(-5%)
Relatively smaller thalamic volume (-4%)
Larger basal ganglia( especially globus pallidus) 
Characteristics of Structural imaging 
findings in schizophrenia
Differences are readily apparent in discordant 
monozygotic twins
Differences are present in first-episode, 
untreated patients, and high-risk and 
unmedicated individuals.
No convincing evidence of heterogeneity            
( e.g.. Subtypes or gender differences),   
although this remains controversial.
The alterations are not seen in Bipolar Disorder 
to the same extent.
Histological findings in schizophrenia.
0 no good evidence, +/- equivocal data,
+ to ++++ increasing amount of supportive data
finding Weight of 
evidence
Lack of neurodegenerative lesion( eg.Alzheimer 
Changes)
+++++
Lack of Gliosis ++++
Smaller cortical hyppocampal pyramidal Neurons +++
Decreased Cortical and Hippocampal Synaptic 
markers
++
Decreased Dendritic Spine Density ++
Loss of Neurons from Dorsal thalmus ++
Abnormalities of white matter neurons +
Entorhinal Cortex Dysplasia +
Disarray of hippocampal neuron orientation +/-
Loss of hippocampal or cortical neurons 0
Histological and Molecular 
pathology in Schizophrenia
Gliosis & Neurodegeneration
Neuronal Cytoarchitecture 
Synapse & dendrites.
Location and extent of pathology
Neurochemistry of schizophrenia
Dopamine
Serotonin
Glutamate
Gama-aminobutyric acid ( GABA)
Dopamine
Main postmortem 
Findings
Other supportive 
evidence
Increased Density of D2 
receptors
DA – releasing agent 
produce psychosis
Decreased Cortical DA 
innervation
All antipsychotics are D2 
Receptor antagonists
Increased D4 –like 
receptor binding 
Increased striatal DA 
release in vivo
Alteration in D3 receptor 
splicing
Glutamate
Main Postmortem findings Other supportive evidence
Decreased presynaptic 
markers
NMDA receptor antagonists 
produce schizophrenia-like 
psychosis
Decreased HC AMPA and 
kinetic receptor expression
Roles of NMDA in 
development and 
neurotoxicity
Minor changes in FC NMDA 
receptor subunits
Partial NMDA agonists have 
some therapeutic benefits
Altered Glutamate fibers in 
cingulate cortex
5-HT
Main Postmortem 
findings
Other supportive 
evidence
Decreased FC  5-HT 2Areceptor 
expression
5-HT 2 agonists e.g. LSD are 
psychotomimetic
Increased FC 5-HT 1A receptors 5-HT 2 receptor polymorphism 
associated with schizophrenia and 
clozapine response
Increased 5-HT transporter affinity Atypical antipsychotics have high 
affinity for several 5-HT receptors
Developmental and trophic role of 
5-HT
GABA
Main Postmortem findings Other supportive 
evidence
Decreased base density of FC GABAergic 
terminals
Role of GABA in 
stress and 
Neurotoxicity
Increased GABA,A receptor subunits
Increased GABA , A , receptor binding in limbic 
areas
Decreased FC expression of glutamic acid 
decarboxylase
Altered density of cingulate GABAergic cells
Some questions 
for postmortem studies 
Which of the cytoarchetectural and synaptic alterations 
are robust?
Is there a single pathology or several?
How are the structural and neurochemical findings 
related?
Does the neuropathology underlie the aberrant 
functional connectivity?
Does the neuropathology relate to psychotic 
symptoms or cognitive deficits?
Are the changes diagnostically specific?
Dopamine in schizophrenic brain
Brain Imaging as a tool for measuring DA 
synaptic activity.
Imaging amphetamine-induced DA release in 
Schizophrenia.
Imaging baseline DA activity in schizophrenia.
Cortical Regulation of subcortical DA 
transmission
Schizophrenia and endogenous sensitization.
DA hyperactivity, neuroplasticity, and positive 
symptoms.
Implications for treatment
Gene Neurodevelopmental 
abnormality
Developmental Insult
Deficient cortical control
Of Subcortical DA activity
Increased subcortical DA release
( stress-related)
Stress
Sustained Subcortical DA release
(Non Stress-Related)
Altered information flow
In corticostriatothalamocortical loops
(DA-Dependent)
Long term plasticity Chronic Psychotic State
( Treatment- unresponsive)
Psychotic episode
( treatment-Responsive)
Endogenous
sensitization
(-)
Treatment
No
Treatment
Q1. Whether the disease would 
develop or NOT?
Q2. If so, when?
Q3.whether it would be treatment 
responsive or resistant? 
Q4.If treatment responsive ,Will it 
Relapse or NOT?
Only partly answered 
Genetic loading
Developmental Insult
Genetic Expression : time, speed, 
specificity, partial/ complete 
expression.
Stress factors
Biochemical dysregulation
Neuronal plasicity
Violence in schizophrenia
Where is the evidence?
Predicting violence 
Clinical implications
Predictors of violence common to 
patients with clinically stable 
schizophrenia and the General 
population
Sociodemographic factors( age, gender, 
economic status and unemployment)
Drug abuse
Antisocial personality
Family history of violence
Previous violence
Clinical predictors of violence in 
schizophrenic patients with exacerbation 
of psychotic symptoms
Type and characteristic of delusions.
-delusions causing fear and anguish.
- persecutory delusions
- active seeking of information to confirm or refute the 
delusional belief.
- systematization and conviction of the delusion
- quality of hallucination
Previous violence
Less insight into symptoms
Higher PANSS general psychopathology score
Approach to reducing 
noncompliance
Use of depot medications
Patient recognition of need of treatment
Close monitoring to adherence.
Use of drugs with better side-effect 
profiles.
Subjective experience.
Future actions
Treatment programme that are effective in prevention of 
violence.
Investigation of the variables associated with violence 
that are amenable to therapeutic approaches.
Strategies to increase compliance with treatment.,which 
may translate into a reduction in number of violent 
episodes and fewer psychotic relapses.
Treatment reducing poor impulse control.
Competent well developed community support and 
comprehensive mental health follow up to identify and 
successfully deal with early signs of violent behaviour.
Development of validated instruments for assessment of 
future violence
Conventional Antipsychotics
Not effective in 50% & in NS;
SE, EPS, TD, PRL,NMS
SE contributes to treatment
nonadherence 
Relapse
Rehospitalization
To minimize SE
Lowering the Dose
Decreases SE
decreases Efficacy 
& Relapse
CAPD do not reduce 
all symptoms and  
& disability in 
Schizophrenia.
At least 50% patients live 
with persistent, residual 
Symptoms;
at least 20% relapse 
Despite adequate doses.
substantial % continue 
as severely disabled, 
frequently relapse,
Conventional antipsychotics
Despite substantial data from controlled 
trials that support the efficacy of CAPD for 
the positive symptoms, the effectiveness of 
these agents in everyday clinical practice is 
substantially less than their efficacy as 
determined by controlled trials.
Although many factors may be involved, 
we do not know all the causes of this
Efficacy-effectiveness gap
Antipsychotics: 
Second generation
Action of CAPD involves D2 blockade in 
limbic system and striatum.
Receptor blockade in limbic system is basis  
for antipsychotic action.
Reduction of activity in striatum is related to 
EPS & TD.
D2 blockade of HPA-axis leads to 
hyperprolactaemia.
Newer drugs have lesser affinity to D2; 
and greater affinity to other receptors 
like 5 HT,NA [alpha 1 & 2],
ability to modulate glutamate receptor-
mediated functions and behavior.
Antipsychotics: 
Second generation
Typical characteristic of atypicals is a ‘low 
D2 & 5- HT Ratio’.
There is some degree of regional anatomical 
specificity. [very little effect on corpus 
striatum].
Various claims have lead to a debate.
Question of well-being of  millions suffering 
from schizophrenia and a billion dollars of 
costs.
If the additional cost of atypical is justified by 
potential benefit? To influence clinicians and 
policy makers.
Antipsychotics: Second generation
Claim of superior efficacy and 
safety have been made but ‘the 
evidence’ is variable and often 
‘inadequate’.
Antipsychotics:
Second generation
There is now strong evidence that AAPD 
are efficacious and have less SE [ low risk 
of EPS ] than CAPD.
However, comprehensive understanding of 
nature and extent of any ‘clinical 
advantages’ of AAPD over CAPD, is not 
available.                                                          
( Leucht S, et al , Aust. N Z J.Psychiat.1998).
The advantage of EPS and TD might 
be offset by disadvantage of other 
SE e.g. weight gain, DM, glucose 
metabolism, hyperlipidaemia
Existing studies have found that atypical 
antipsychotics cause fewer EPSs side effects 
than their conventional counterparts, 
especially when the conventional comparator 
is haloperidol.
In spite of marketing claims, studies of effect 
on cognitive functions are wholly 
inconclusive, as are effect on mood 
symptoms.
The effects of AAPD on
Long-term outcome
Relapse prevention
Social and vocational functioning
Suicide prevention
Quality of life
Family and caregivers burden
Have just begun to be explored
Risperidone, olanzapine and Quetiapine 
account for > 50% of the prescriptions 
of New Antipsychotics in North 
America.
The rate of usage in other countries 
varies from 5% to 40% .
Usage - AAPD
Patients who had inadequate response to 
conventional antipsychotics or who suffered 
problematic side effects are the first to be 
switched to atypical APD.
Now, however , many newly diagnosed or    
first-episode patients are initially prescribed 
these newer agents with the hope ( not yet 
backed by evidence ) of giving them very 
early advantage.[ Lieberman JA, JCP, 1996]  
Even if atypical antipsychotic drugs do not 
decrease the overall cost of care, their usage 
may be warranted if their benefits are judged  
to be substantial enough to justify the 
increased expenditure.
.  
Atypical agents are several time more 
expansive, average being $ 5000 or more per 
patient per year.
Currently the cost-effective justification, 
in scarce resources of public health, 
does not hold valid
This is important because the spending of 
large sum of money on treatments that are 
less cost-effective than available alternatives 
may result in needless waste of scarce 
resources and deprive some patients of 
clinical benefits to which they would 
otherwise have access.
The clinical and public policy decision to 
supplant conventional with atypical APD 
requires empirical evidence.
Existing evidence does not adequately 
address the long-term effectiveness and cost 
issue.
Studies designed to obtain FDA permission [ 
6-8 weeks trials] do not definitively 
demonstrate    “the real World” effect of 
AAPD.
The evidence to support  the superior 
effectiveness of atypical APD is currently 
limited and predominantly based on short-term 
efficacy studies.
Schizophrenia : Family Studies and 
Treatment of spectrum disorders.
Eversince the disease was described by Kraepeline, 100 
years back, treatments have been in progress.Major 
advances are noticed That:
Treatment of schizophrenia and other mental disorders 
have become more Humane and now alinged more 
closely to other medical disorders.
Antipsychotics have become the first line of defence ,and  
have improved the lives of most patients.
A greater understanding of the genetic basis of 
schizophrenia underlies much of the recent progess, in 
part through its focus on reliable diagnosis.
One consequence of Genetic studies is the 
recognition that schziophrenia illness is broader 
than the DSM or ICD diagnosis of schziophrenia, 
and exists as a “ Spectrum” of conditions.
While some spectrum disorders are as severe 
as schizophrenia like schizo-affective disorder, 
others are milder and do not involve psychosis 
eg. Schizoptypal personality disorder [ SPD]
The spectrum concept has 
numerous implications for 
treatment.
Therapeutic efforts vary across schizophrenia 
spectrum disorders as function of both severity 
and type of symptoms.
These differences are of grate importance in 
understanding the core features of 
schizophrenia.
Fact that ‘psychosis is not a major feature of 
spectrum disorder’ suggests that other more 
subtle symptoms might better reflect underlying 
etiology.
If such deficits are identifiable, they 
may provide foundation for treatment 
strategies
Moreover, if they are identifiable early, 
they may even prevent psychosis.
Discussion on spectrum disorder should 
focus  on reflections of genetic 
predisposition.
There is a need to redefine and 
reformulate Meehl’s notion of ‘schizotaxia’.
Scizotaxia is perhaps the core liability for 
Schizophrenia and spectrum disorder.
Schziophrenic
patient
The relatives
Normal –
asymptomatic
Relatives with 
Nonpsychotic 
illness
Relatives with 
alcoholism
Relatives with
Mood Disorder
Relatives with 
other
Psychiatric illness
Relatives with other 
Psychotic illness
Relatives with 
schziophrenia
Relatives with
Psychotic affective 
disorder
Relatives with
Alcoholism 
Comorbid 
schizophrenia
Relatives with
Schizotypal personality
disorder
Relatives with schizophrenia
Spectrum disorder
Family
studies
Lessions from family studies of nonpsychotic 
relatives of schizophrenic illness
Progress in identification of neuropsychological and 
structural brain abnormalities in the relatives.[ mainly first 
–degree ].Data show :-
(i) relatively specific N-Psy. deficits in both, patients and 
their relatives.
(ii) the stability of these deficits over time.
(iii) the structural and functional brain abnormalities in 
patients and relatives.
(iv) the effect of genetic loading on N-Psych. Functions 
and neuroanatomical structures.
These findings form foundation of current 
efforts to define, validate and treat ‘schizotaxia’
Neuropsychological functions among 
adult relatives : functions studied
1. Abstraction / 
executive memory
2. Verbal ability
3. Spatial ability
4. Verbal memory
5. Visual memory
6. Verbal memory
7.Learning
8.Perceptual-motor 
speed
9.Mental 
control/encoding
10.Motor functions
11.Auditory attention
Findings in controlled studies
The relatives performed more poorly and had greater 
variability on three predicted functions : 
1.abstarction/ executive function.2.verbal memory 
3.auditory attention/vigilance .
Lower scores on mental control and verbal ability.
Showed more variability on learning and motor 
ability.
Two groups did nor differ on visual ability, visual 
memory, or perceptual motor function.
The deficits observed did not account for by 
psychopathology in relatives, by level of education 
or parental social class.
Findings in controlled studies
Neuropsychological measures might be useful in 
detecting putative carriers of the schizophrenia 
genotype, who cannot be detected with psychiatric 
assessment.
These are at best the ‘ risk indicators for underlying 
vulnerability to schziophrenia.
It could be hypothesised that ,if the expression of 
neuropsychological risk indicators in the relatives was 
due to an underlying genotype ,then the 
neuropsychological indicators of schziophrenia  
genotype would intercorrelate to a greater degree within 
the relative’s group.
Men with schizophrenia have greater degree of 
neuropsychological deficits that women.
Stability of neuropsychological 
deficits 
0.7%
1%
1%1%
Core/ deficit 
Schizophrenia
Schizophrenia
Schizotypal
Personality
Disorder
Affective
schizophrenia
Decreasing Genetic Risk
for schizophrenia in 
Relatives
Increasing Genetic Risk
for affective Disorders
and alcoholism in Relatives
1% 1% 1%1%
Schizophrenia and spectrum Disorder: 
Genetic phenomenology

